Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

Reports Q3 revenue $6.78M, consensus $4.71M. Kirk Huntsman, Vivos’ chairman and CEO, stated, “We are very pleased to announce that our third quarter sequential revenue was up 78%, while same period year-over-year revenue increased 76%. This outstanding quarterly revenue increase represents exactly what we anticipated when we announced and executed our strategic pivot away from our historical reliance on a dental industry distribution channel and toward a direct affiliation with, or acquisition of, medical sleep practices and testing centers. This pivot was showcased by our June 2025 acquisition of The Sleep Center of Nevada.”